Whole Blood Specimen Collection From Pregnant Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02430584

Recruitment Status : Recruiting

First Posted : April 30, 2015

Last Update Posted : August 21, 2019

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Progenity, Inc.

Study Description

Brief Summary:

To obtain whole blood specimens from pregnant subjects to be used for research and development and clinical validation studies of prenatal assays.

Condition or disease	Intervention/treatment
Down Syndrome Edwards Syndrome Patau Syndrome Klinefelter Syndrome Turner Syndrome DiGeorge Syndrome Perinatal Infections	Other: Observational - no intervention

Detailed Description:

This sample collection protocol allows for the identification, recruitment, and participation in women who are pregnant and are known to:

be at an increased risk for fetal genetic abnormalities
be at increased risk for congenital fetal infection by virtue of being positive by initial screening tests, or are known to have an active infection during this pregnancy.
possess irregular blood group antigens (the subject or the father of the baby) and are therefore at increased risk for fetal sensitization during this pregnancy.

Study Design

Layout table for study information

Study Type :	Observational
Estimated Enrollment :	5000 participants
Observational Model:	Family-Based
Time Perspective:	Prospective
Official Title:	Whole Blood Specimen Collection From Pregnant Subjects
Actual Study Start Date :	March 2015
Estimated Primary Completion Date :	March 2020
Estimated Study Completion Date :	May 2020

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Turner syndrome Trisomy 13 Trisomy 18

Genetic and Rare Diseases Information Center resources: Gonadal Dysgenesis Turner Syndrome Trisomy 13 Trisomy 18 Shprintzen-Goldberg Craniosynostosis Syndrome 22q11.2 Deletion Syndrome Chromosomal Triplication Lymphatic Malformations Hypoparathyroidism

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

Whole blood collection [ Time Frame: One or more monthly clinic visits (≥25 days apart) over 13 weeks ]

Biospecimen Retention: Samples With DNA

Study will collect up to 50 mL of whole blood at one or more monthly clinic visits (≥25 days apart) from pregnant women carrying a single fetus of 10 to 26 weeks of gestational age

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

GENDER: Female ETHNICITY: All ethnicities RACE: All races AGE: Subjects 18 years of age or older

Criteria

Inclusion Criteria:

Subject willing to provide consent to have up to 50 mL of whole blood collected at one or more monthly (≥25 days) clinic visits
Subject is pregnant carrying a singleton fetus of 10 to 26 weeks gestational age inclusive
Subject is 18 years of age or older
Subject is at an increased risk for one or more of the following:
- fetal gene and chromosome abnormalities
- congenital fetal infection
- known to possess irregular blood group antigens (subject or father of the baby)
- known to have some other condition amenable to noninvasive prenatal testing

Exclusion Criteria:

Pregnancy is non-viable

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02430584

Contacts

Layout table for location contacts

Contact: Peter Stiegler, PhD	760-494-1743	clinical.affairs@progenity.com

Locations

Layout table for location information

United States, Tennessee
Regional Obstetrical Consultants	Recruiting
Chattanooga, Tennessee, United States, 37403
Contact: C. David Adair, MD 423-664-4460
Contact: Lorrie Mason, NNP 423-664-4460

Sponsors and Collaborators

Progenity, Inc.

More Information

Layout table for additonal information

Responsible Party:	Progenity, Inc.
ClinicalTrials.gov Identifier:	NCT02430584 History of Changes
Other Study ID Numbers:	PRO-101-SAMPLES
First Posted:	April 30, 2015 Key Record Dates
Last Update Posted:	August 21, 2019
Last Verified:	January 2019

Additional relevant MeSH terms:

Layout table for MeSH terms

DiGeorge Syndrome Down Syndrome Trisomy 13 Syndrome Turner Syndrome Klinefelter Syndrome Trisomy 18 Syndrome Syndrome Disease Pathologic Processes Intellectual Disability Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Abnormalities, Multiple Congenital Abnormalities	Chromosome Disorders Genetic Diseases, Inborn Gonadal Dysgenesis Disorders of Sex Development Urogenital Abnormalities Sex Chromosome Disorders of Sex Development Heart Defects, Congenital Cardiovascular Abnormalities Cardiovascular Diseases Heart Diseases Sex Chromosome Disorders Gonadal Disorders Endocrine System Diseases Hypogonadism 22q11 Deletion Syndrome

To Top